With a Goldilocks economy and a bull market charging into a second year, 2024 shaped up to be a good year for investors. Now, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The largest project underway is Novo Nordisk’s $4.1 billion expansion in Johnston County ... Amgen is also growing its local ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

Denmark-based Novo Nordisk told The Progress-Index in an email ... Signs outside of AMPAC’s 600,000 square-foot facility on Normandy Drive, however, have been changed to reflect the new owners.

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company’s experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patien ...

Novo Nordisk falls most on record after new weight drug disappoints Novo’s shares plunged as much as 27 per cent, and they’re now down 17 per cent for the year after a previous runup on the strength ...

In response to this move from Danish authorities, a NovoNordisk spokesperson said: 'After a thorough evaluation of the studies from the University of Southern Denmark and Novo Nordisk’s internal ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...

Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...